Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Inclusion Criteria: * Informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up. * Age ≥ 18 years or legal age of consent if greater than 18 years. * Histologic diagnosis of solitary fibrous tumor (stratum 1) or extraskeletal myxoid chondrosarcoma (stratum 2) (unresectable, locally advanced or metastatic disease) confirmed by central pathology review. * Patients with metastatic tumor suitable for complete resection can be recruited. In absence of progressive disease these patients should be treated with the study drug for at least 6 months. * For patients who have received previous anticancer treatments, progressive disease must be demonstrated within 6 months prior to enrollment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Measurable disease according to Choi (SFT) and RECIST 1.1 (EMC) criteria. * Patients could have received a maximum of 4 lines of chemotherapy for metastatic disease prior to trial enrollment. * Patients must be able to swallow and retain the study drug. * Adequate organ system function as defined in protocol. * Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment. All patients (both male and female) must agree to use effective contraception methods, as defined in the protocol. * Left ventricular ejection fraction (LVEF) above the lower limit of normal for the institutio…